<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041011</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-Ib-106</org_study_id>
    <nct_id>NCT04041011</nct_id>
  </id_info>
  <brief_title>A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients</brief_title>
  <official_title>A Phase Ib Study of SHR-1316 in Combination With Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination
      with Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: 1.Number of Participants with AEs and SAEs</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: 2. RP2D: Recommended dose for phase II study</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: 1. ORR: Percentage of Participants With a CR or PR</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: 1. ORR: Percentage of Participants With a CR or PR</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: 1.Number of Participants with AEs and SAEs</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: 2.DoR: Percentage of Participants With a CR or PR</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: 3. DCR: Percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: 4. PFS: PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: 5. OS: Baseline until death from any cause</measure>
    <time_frame>Up to approximately 24 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1.Experimental: A (Part 1): Fluzoparib and SHR -1316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.Experimental: B (Part 1): Fluzoparib and SHR -1316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.Experimental: A (Part 1): Fluzoparib and SHR -1316</intervention_name>
    <description>1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).</description>
    <arm_group_label>1.Experimental: A (Part 1): Fluzoparib and SHR -1316</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.Experimental: B (Part 1): Fluzoparib and SHR -1316</intervention_name>
    <description>2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).</description>
    <arm_group_label>2.Experimental: B (Part 1): Fluzoparib and SHR -1316</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion</intervention_name>
    <description>3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).</description>
    <arm_group_label>3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age.

          -  Histologically or cytologically confirmed SCLC.

          -  Failed at least one prior line of platinum-based chemotherapy.

          -  Patients must have measurable disease as defined by RECIST v1.1.

          -  ECOG 0-1.

          -  Adequate hematologic and organ function

          -  Signed inform consent form

        Exclusion Criteria:

          -  Active or untreated central nervous system (CNS) metastases

          -  Spinal cord compression not definitively treated with surgery and/or radiation .

          -  Leptomeningeal disease

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures

          -  Malignancies other than SCLC within 5 years prior to randomization

          -  History of autoimmune disease

          -  Positive test result for human immunodeficiency virus (HIV)

          -  Active hepatitis B or hepatitis C

          -  Severe infections

          -  Subjects with a condition requiring systemic treatment with either corticosteroids
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of first administration of study treatment.

          -  Significant cardiovascular disease

          -  Prior allogeneic bone marrow transplantation or solid organ transplant

          -  Treatment with systemic immunosuppressive medications prior to randomization

          -  Pregnant or lactating women

          -  History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the study, interfere with the subject's participation
             for the full duration of the study, or is not in the best interest of the subject to
             participate, in the opinion of the treating investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianjun Zou</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu HengRui Medicine Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Zou</last_name>
    <phone>02168868570</phone>
    <phone_ext>02168868570</phone_ext>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

